Xeris Biopharma Holdings
XERS
97 hedge funds and large institutions have $71.6M invested in Xeris Biopharma Holdings in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 29 reducing their positions, and 16 closing their positions.
1,909% more call options, than puts
Call options by funds: $1.91M | Put options by funds: $95K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 29
2.5% less ownership
Funds ownership: 42.11% → 39.61% (-2.5%)
4% less funds holding
Funds holding: 101 → 97 (-4)
20% less capital invested
Capital invested by funds: $89.3M → $71.6M (-$17.7M)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$980K |
| 2 |
BlackRock
New York
|
+$491K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$267K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$125K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.91M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.45M |
| 3 |
SC
Sinecera Capital
Austin,
Texas
|
-$395K |
| 4 |
DAM
Deltec Asset Management
New York
|
-$239K |
| 5 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
-$117K |
XERS Hedge Fund Activity: Q4 2022 in Review
97 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2022, worth a combined $71.6M — down 20% from $89.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of XERS and 12 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $980K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.91M sold.
- 97 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2022, down from 101 in Q3 2022.
- Funds reported $71.6M of Xeris Biopharma Holdings stock for Q4 2022, down 20% quarter-over-quarter.
- 12 funds opened new Xeris Biopharma Holdings positions in Q4 2022 and 16 closed out, a net change of -4 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2022 was Millennium Management, an estimated $980K added.
- The largest Xeris Biopharma Holdings seller in Q4 2022 was Armistice Capital, an estimated $3.91M sold.
Based on aggregated 13F filings for Q4 2022.